drugset / Trial / NCT02034591

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

NCT02034591

Phase 1 Completed 37 enrolled Bristol-Myers Squibb Pfizer · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the bioavailability of Apixaban oral solution administered through an Nasogastric Tube (NGT) in the presence of Boost® Plus and Apixaban administered as crushed tablet through a nasogastric tube relative to Apixaban solution administered orally in healthy subjects.

Timeline

Start
2011-10
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 5 mg Oral

Indications

No indication recorded.